LKFT logo

Lakefront Biotherapeutics (LKFT)

$34.79

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on LKFT

Market cap

$2.29B

EPS

5.72

P/E ratio

5.2

Price to sales

1.52

Dividend yield

--

Beta

0.22131

Price on LKFT

Previous close

$33.98

Today's open

$34.50

Day's range

$34.45 - $35.15

52 week range

$25.68 - $36.24

Profile about LKFT

CEO

Henry Gosebruch

Employees

452

Headquarters

Mechelen,

Exchange

Nasdaq Global Select

Shares outstanding

65897071

Issue type

American Depository Receipt

LKFT industries and sectors

Healthcare

Biotechnology & Life Sciences

News on LKFT

Lakefront Initiates New €50 Million Share Repurchase Program Following Completion of Initial Share Repurchase Program

Mechelen, Belgium; November 16, 2026; 7.30 AM CET regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced the initiation of a new share repurchase program of up to €50 million, following completion of its initial €50 million program announced on June 9, 2026.

news source

GlobeNewsWire • Nov 16, 2026

news preview

Lakefront Biotherapeutics Reports Nine Months 2026 Financial Results and Provides Business Update

Gamgertamig poster accepted for presentation at the 2026 ASH 1 Annual Meeting, featuring data from ongoing Phase 1b studies that suggest potential to retain remission after B cell reconstitution, maintained in the absence of background therapy for autoimmune cytopenias, consistent with an “immune reset”

news source

GlobeNewsWire • Nov 11, 2026

news preview

Lakefront to Present at the 2026 Jefferies Global Healthcare Conference in London

Mechelen, Belgium; November 10, 2026, 22.01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the Company will host a fireside chat at the 2026 Jefferies Global Healthcare Conference in London at 2:00 pm GMT (9:00 am ET) on Tuesday, November 17, 2026.

news source

GlobeNewsWire • Nov 10, 2026

news preview

Should You Buy Lakefront Biotherapeutics - Sponsored ADR (LKFT) After Golden Cross?

Lakefront Biotherapeutics - Sponsored ADR (LKFT) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, LKFT's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

news source

Zacks Investment Research • Nov 6, 2026

news preview

Lakefront Biotherapeutics Announces Poster Presentation at the 2026 American Society of Hematology Meeting

Gamgertamig data from ongoing Phase 1b studies suggest potential to retain remission after B cell reconstitution, maintained in the absence of background therapy for autoimmune cytopenias, consistent with an “immune reset ”

news source

GlobeNewsWire • Nov 4, 2026

news preview

Lakefront Biotherapeutics Welcomes Dr. Mehdi Shahidi to its Board of Directors

Dr. Shahidi brings extensive drug development experience, regulatory success, and transformative operational expertise to the Board

news source

GlobeNewsWire • Nov 2, 2026

news preview

Lakefront Biotherapeutics - Sponsored ADR (LKFT) Upgraded to Buy: What Does It Mean for the Stock?

Lakefront Biotherapeutics - Sponsored ADR (LKFT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

news source

Zacks Investment Research • Oct 21, 2026

news preview

Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics

Previously announced wind-down of the legacy cell therapy activities is substantially complete  Mechelen, Belgium; October 14, 2026, 22.01 CEST; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that it has completed the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics BV, a Belgium-based biotechnology company developing next-generation armed CAR-T therapies for cancer and formed by experienced executives Paul Stoffels, John Mellors and Peter Verhaeghe. The preclinical program is based on technology originated from, and research undertaken by AboundBio, which was acquired by Lakefront NV (previously Galapagos NV) in 2022.

news source

GlobeNewsWire • Oct 14, 2026

news preview

Acquisition of Own Shares

Mechelen, Belgium; October 13, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between October 05, 2026 and October 09, 2026 it has repurchased 126,322 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 10/5/2026 XAMS 20,641 26.14 539,466.98 25.78 26.50 10/5/2026 TQEX 442 26.01 11,497.92 25.90 26.04 10/5/2026 CEUX 2,656 25.97 68,975.52 25.82 26.22 10/5/2026 AQEU 174 25.88 4,503.12 25.88 25.88 10/6/2026 XAMS 20,421 26.40 539,130.74 25.94 26.64 10/6/2026 TQEX 1,383 26.54 36,708.97 26.20 26.64 10/6/2026 CEUX 2,620 26.51 69,458.30 26.42 26.64 10/6/2026 AQEU 679 26.59 18,051.55 26.44 26.64 10/7/2026 XAMS 22,325 26.15 583,776.43 25.86 26.54 10/7/2026 CEUX 2,566 26.16 67,136.05 25.90 26.48 10/7/2026 AQEU 506 26.18 13,246.17 26.00 26.50 10/8/2026 XAMS 22,557 26.20 591,027.24 25.82 26.78 10/8/2026 TQEX 150 26.27 3,940.01 26.24 26.34 10/8/2026 CEUX 2,158 26.27 56,690.44 26.20 26.36 10/8/2026 AQEU 817 26.20 21,408.91 26.20 26.22 10/9/2026 XAMS 21,498 26.40 567,643.94 26.18 26.66 10/9/2026 TQEX 592 26.38 15,616.60 26.34 26.46 10/9/2026 CEUX 3,394 26.37 89,516.07 26.34 26.44 10/9/2026 AQEU 743 26.40 19,612.97 26.34 26.46 Total   126,322 26.26 3,317,407.94 25.78 26.78 As of market close on October 9, 2026, Lakefront holds 1,877,353 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

news source

GlobeNewsWire • Oct 13, 2026

news preview

Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig

Lakefront Biotherapeutics American Depositary Shares NASDAQ: LKFT said it plans to begin registrational studies next year for its lead T-cell engager, gamgertamig, following a broad restructuring of its legacy cell-therapy operations and the acquisition of assets from Ouro Medicines.

news source

MarketBeat • Sep 21, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Lakefront Biotherapeutics

Open an M1 investment account to buy and sell Lakefront Biotherapeutics commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in LKFT on M1